Back to Search
Start Over
RNA-based therapies: A cog in the wheel of lung cancer defense
- Source :
- Molecular Cancer, Molecular Cancer, Vol 20, Iss 1, Pp 1-24 (2021)
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Lung cancer (LC) is a heterogeneous disease consisting mainly of two subtypes, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), and remains the leading cause of death worldwide. Despite recent advances in therapies, the overall 5-year survival rate of LC remains less than 20%. The efficacy of current therapeutic approaches is compromised by inherent or acquired drug-resistance and severe off-target effects. Therefore, the identification and development of innovative and effective therapeutic approaches are critically desired for LC. The development of RNA-mediated gene inhibition technologies was a turning point in the field of RNA biology. The critical regulatory role of different RNAs in multiple cancer pathways makes them a rich source of targets and innovative tools for developing anticancer therapies. The identification of antisense sequences, short interfering RNAs (siRNAs), microRNAs (miRNAs or miRs), anti-miRs, and mRNA-based platforms holds great promise in preclinical and early clinical evaluation against LC. In the last decade, RNA-based therapies have substantially expanded and tested in clinical trials for multiple malignancies, including LC. This article describes the current understanding of various aspects of RNA-based therapeutics, including modern platforms, modifications, and combinations with chemo-/immunotherapies that have translational potential for LC therapies.
- Subjects :
- 0301 basic medicine
Cancer Research
Small interfering RNA
Lung Neoplasms
Drug Evaluation, Preclinical
Review
Disease
Biology
lcsh:RC254-282
Cancer Vaccines
anti-miRs
03 medical and health sciences
RNA interference
0302 clinical medicine
microRNA
Biomarkers, Tumor
medicine
Animals
Humans
RNA, Antisense
RNA, Messenger
Lung cancer
Survival rate
Antisense oligonucleotides
Clinical Studies as Topic
Antagomirs
RNA
Genetic Therapy
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Combined Modality Therapy
Clinical trial
MicroRNAs
Treatment Outcome
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Cancer research
Molecular Medicine
mRNA-vaccine
Subjects
Details
- ISSN :
- 14764598
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- Molecular Cancer
- Accession number :
- edsair.doi.dedup.....027a958c06246c0f8349e78af26e13fa
- Full Text :
- https://doi.org/10.1186/s12943-021-01338-2